Keith A Josephs

List of Publications by Year
in descending order

334 papers	31,998 citations	6592 79 h-index	5101 166 g-index
338 all docs	338 docs citations	338 times ranked	19108 citing authors

#	Article	IF	Citations
1	APOE Îµ4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 784-796.	0.4	7
2	Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia. Journal of the International Neuropsychological Society, 2022, 28, 441-451.	1.2	1
3	Relationship Between ¹⁸F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies. Journal of Nuclear Medicine, 2022, 63, 931-935.	2.8	9
4	Autopsy Validation of Progressive Supranuclear Palsyâ€Predominant Speech/Language Disorder Criteria. Movement Disorders, 2022, 37, 213-218.	2.2	6
5	Diffuse Lewy body disease presenting as Parkinson's disease with progressive aphasia. Neuropathology, 2022, 42, 82-89.	0.7	4
6	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	1.4	3
7	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
8	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. NeuroImage: Clinical, 2022, 34, 102999.	1.4	11
9	Does limited EMG denervation in early primary lateral sclerosis predict amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 554-561.	1.1	2
10	Posterior cortical atrophy: Primary occipital variant. European Journal of Neurology, 2022, 29, 2138-2143.	1.7	7
11	A Preliminary Report of Network Electroencephalographic Measures in Primary Progressive Apraxia of Speech and Aphasia. Brain Sciences, 2022, 12, 378.	1.1	1
12	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. Brain, 2022, 145, 2472-2485.	3.7	6
13	Depression and Apathy across Different Variants of Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2022, 9, 212-217.	0.8	8
14	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. Movement Disorders, 2022, 37, 702-712.	2.2	14
15	Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100Âyears. Journal of Neurology, 2022, 269, 4030-4054.	1.8	5
16	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Communications, 2022, 4, .	1.5	5
17	Cross-Sectional and Longitudinal Assessment of Behavior in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. Dementia and Geriatric Cognitive Disorders, 2022, 51, 193-202.	0.7	1
18	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathologica, 2022, 144, 159-160.	3.9	14

#	Article	IF	Citations
19	Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant. NeuroImage: Clinical, 2022, 35, 103030.	1.4	8
20	Old age amyotrophic lateral sclerosis and limbic TDPâ€43 pathology. Brain Pathology, 2022, 32, .	2.1	6
21	Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy. Parkinsonism and Related Disorders, 2022, 101, 9-14.	1.1	2
22	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 1693-1706.	1.6	44
23	Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt <scp>Alphaâ€Synucleinopathies</scp>. Annals of Neurology, 2021, 89, 293-303.	2.8	12
24	Primary progressive apraxia of speech: from recognition to diagnosis and care. Aphasiology, 2021, 35, 560-591.	1.4	45
25	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. Annals of Neurology, 2021, 89, 520-533.	2.8	21
26	Association of amyloid angiopathy with microbleeds in logopenic progressive aphasia: an imagingâ€pathology study. European Journal of Neurology, 2021, 28, 670-675.	1.7	6
27	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 17-28.	0.7	5
28	Phonological Errors in Posterior Cortical Atrophy. Dementia and Geriatric Cognitive Disorders, 2021, 50, 195-203.	0.7	8
29	Progressive Supranuclear Palsy and Corticobasal Degeneration. Advances in Experimental Medicine and Biology, 2021, 1281, 151-176.	0.8	10
30	A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech. Journal of Speech, Language, and Hearing Research, 2021, 64, 392-404.	0.7	7
31	Natural History of â€œPureâ€•Primary Lateral Sclerosis. Neurology, 2021, 96, e2231-e2238.	1.5	9
32	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. Neurocase, 2021, 27, 212-222.	0.2	4
33	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. Journal of Neurology, 2021, 268, 3409-3420.	1.8	12
34	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. Journal of Alzheimer's Disease, 2021, 80, 683-693.	1.2	7
35	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
36	A Cognitive Psychometric Investigation of Word Production and Phonological Error Rates in Logopenic Progressive Aphasia. American Journal of Speech-Language Pathology, 2021, 30, 1194-1202.	0.9	0

#	Article	IF	Citations
37	Old age genetically confirmed frontotemporal lobar degeneration with TDPâ€43 has limbic predominant TDPâ€43 deposition. Neuropathology and Applied Neurobiology, 2021, 47, 1050-1059.	1.8	10
38	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. Journal of Neurology, 2021, 268, 4752-4758.	1.8	5
39	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452.	5.8	34
40	Neurodegeneration of the visual word form area in a patient with word form alexia. Neurology and Clinical Neuroscience, 2021, 9, 359-360.	0.2	5
41	Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy. American Journal of Speech-Language Pathology, 2021, 30, 1361-1372.	0.9	12
42	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675.	2.2	4
43	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12
44	Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. Neurology, 2021, 97, 908-909.	1.5	7
45	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
46	Assessing Change in Communication Limitations in Primary Progressive Apraxia of Speech and Aphasia: A 1-Year Follow-Up Study. American Journal of Speech-Language Pathology, 2021, 30, 1-11.	0.9	1
47	Sleep disturbances in the speech-language variant of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2021, 91, 9-12.	1.1	4
48	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	1.5	11
49	In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. Neurology: Clinical Practice, 2021, 11, 10.1212/CPJ.0000000000000755.	0.8	4
50	Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. Neurology: Clinical Practice, 2021, 11, 249-255.	0.8	9
51	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. NeuroImage: Clinical, 2021, 32, 102850.	1.4	13
52	Word Fluency Test Performance in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. American Journal of Speech-Language Pathology, 2021, 30, 2635-2642.	0.9	4
53	Characterizing amyloid positive individuals with normal tau PET levels five years later: An ADNI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
54	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	2.2	37

#	Article	IF	Citations
55	Dysphagia in Progressive Supranuclear Palsy. Dysphagia, 2020, 35, 667-676.	1.0	25
56	Incidence of frontotemporal disorders in Olmsted County: A populationâ€based study. Alzheimer's and Dementia, 2020, 16, 482-490.	0.4	11
57	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	1.1	5
58	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. Parkinsonism and Related Disorders, 2020, 81, 34-40.	1.1	20
59	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 78, 200-203.	1.1	8
60	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
61	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. Neurocase, 2020, 26, 259-263.	0.2	6
62	Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	1.2	7
63	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	1.7	38
64	Curious case of FTD-ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1255-1255.	0.9	0
65	Automated Hippocampal Subfield Volumetric Analyses in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 78, 927-937.	1.2	14
66	Sensitivityâ€“Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	2.8	32
67	Protein contributions to brain atrophy acceleration in Alzheimerâ€™s disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
68	Cerebrovascular pathology and misdiagnosis of multiple system atrophy: An autopsy study. Parkinsonism and Related Disorders, 2020, 75, 34-40.	1.1	8
69	Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. Journal of Neurology, 2020, 267, 2603-2611.	1.8	12
70	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81
71	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.5	27
72	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51

#	Article	IF	Citations
73	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. Neurology, 2020, 95, e35-e45.	1.5	9
74	PSP-like syndrome after aortic surgery in adults (Mokri syndrome). Neurology: Clinical Practice, 2020, 10, 245-254.	0.8	5
75	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	1.5	3
76	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical, 2020, 25, 102152.	1.4	46
77	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
78	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
79	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
80	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. Brain and Language, 2020, 204, 104773.	0.8	15
81	Association between transactive response DNA-binding protein ofÂ43 kDa type and cognitive resilience to Alzheimerâ€™s disease: aÂcase-control study. Neurobiology of Aging, 2020, 92, 92-97.	1.5	13
82	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17
83	Western Aphasia Batteryâ€“Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. American Journal of Speech-Language Pathology, 2020, 29, 498-510.	0.9	24
84	Communication Limitations in Patients With Progressive Apraxia of Speech and Aphasia. American Journal of Speech-Language Pathology, 2020, 29, 1976-1986.	0.9	13
85	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 2020, 130, 6080-6092.	3.9	117
86	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202.	1.5	13
87	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Human Brain Mapping, 2019, 40, 1618-1631.	1.9	53
88	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain and Language, 2019, 197, 104676.	0.8	29
89	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. Alzheimer's and Dementia, 2019, 15, 1218-1228.	0.4	34
90	LATE to the PART-y. Brain, 2019, 142, e47-e47.	3.7	44

#	Article	IF	Citations
91	Multimodal neuroimaging relationships in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 56-61.	1.1	19
92	C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation. Acta Neuropathologica Communications, 2019, 7, 100.	2.4	11
93	Submentalis Rapid Eye Movement Sleep Muscle Activity: A Potential Biomarker for Synucleinopathy. Annals of Neurology, 2019, 86, 969-974.	2.8	14
94	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
95	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1655-1662.	2.2	14
96	Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension. Neurology, 2019, 93, e1339-e1347.	1.5	16
97	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
98	Transient Epileptic Amnesia: A Treatable Cause of Spells Associated With Persistent Cognitive Symptoms. Frontiers in Neurology, 2019, 10, 939.	1.1	17
99	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiology of Aging, 2019, 77, 26-36.	1.5	51
100	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	3.7	33
101	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. Movement Disorders Clinical Practice, 2019, 6, 452-461.	0.8	26
102	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
103	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	1.4	54
104	Brain atrophy in primary ageâ€related tauopathy is linked to transactive response DNAâ€binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.4	14
105	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	2.2	93
106	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 675-685.	0.4	36
107	Rare Tauopathies. Seminars in Neurology, 2019, 39, 264-273.	0.5	4
108	Prominent auditory deficits in primary progressive aphasia: A case study. Cortex, 2019, 117, 396-406.	1.1	14

#	Article	IF	Citations
109	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 1144-1153.	2.2	98
110	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
111	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica, 2019, 137, 227-238.	3.9	65
112	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	2.2	33
113	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
114	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
115	Electroencephalography in primary progressive aphasia and apraxia of speech. Aphasiology, 2019, 33, 1410-1417.	1.4	9
116	[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation. Journal of Neurology, 2018, 265, 1079-1088.	1.8	29
117	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1713-1724.	1.2	45
118	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
119	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	2.8	73
120	Rest in peace FTDP-17. Brain, 2018, 141, 324-331.	3.7	13
121	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex, 2018, 99, 358-374.	1.1	42
122	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 3-9.	1.1	27
123	[¹⁸F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
124	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. Brain, 2018, 141, 302-317.	3.7	42
125	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
126	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97

#	Article	IF	Citations
127	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
128	Disrupted functional connectivity in primary progressive apraxia of speech. NeuroImage: Clinical, 2018, 18, 617-629.	1.4	36
129	Molecular neuroimaging in primary progressive aphasia with predominant agraphia. Neurocase, 2018, 24, 121-123.	0.2	2
130	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
131	A Neuropsychiatric Analysis of the Cotard Delusion. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 58-65.	0.9	32
132	Corticobasal degeneration: key emerging issues. Journal of Neurology, 2018, 265, 439-445.	1.8	27
133	Rapid rate on quasi-speech tasks in the semantic variant of primary progressive aphasia: A non-motor phenomenon?. Journal of the Acoustical Society of America, 2018, 144, 3364-3370.	0.5	5
134	Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech. American Journal of Speech-Language Pathology, 2018, 27, 1303-1318.	0.9	36
135	Association of Apolipoprotein E Îµ4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	4.5	60
136	Patterns of Neuropsychological Dysfunction and Cortical Volume Changes in Logopenic Aphasia. Journal of Alzheimer's Disease, 2018, 66, 1015-1025.	1.2	26
137	Quantitative assessment of grammar in amyloid-negative logopenic aphasia. Brain and Language, 2018, 186, 26-31.	0.8	7
138	Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech. European Journal of Neurology, 2018, 25, 1352-1357.	1.7	12
139	Fitting TDP-43 into the APOE Îµ4 and neurodegeneration story. Lancet Neurology, The, 2018, 17, 735-737.	4.9	3
140	Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65.	0.8	106
141	TDP-43 and Alzheimerâ€™s Disease Pathologic Subtype in Non-Amnestic Alzheimerâ€™s Disease Dementia. Journal of Alzheimer's Disease, 2018, 64, 1227-1233.	1.2	20
142	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.3	4
143	Quantitative Analysis of Agrammatism in Agrammatic Primary Progressive Aphasia and Dominant Apraxia of Speech. Journal of Speech, Language, and Hearing Research, 2018, 61, 2337-2346.	0.7	19
144	Diffuse Lewy body disease manifesting as corticobasal syndrome. Neurology, 2018, 91, e268-e279.	1.5	37

#	Article	IF	Citations
145	The diagnosis of progressive supranuclear palsy: current opinions and challenges. Expert Review of Neurotherapeutics, 2018, 18, 603-616.	1.4	18
146	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase, 2018, 24, 111-120.	0.2	25
147	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica, 2018, 136, 389-404.	3.9	59
148	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
149	Temporal acoustic measures distinguish primary progressive apraxia of speech from primary progressive aphasia. Brain and Language, 2017, 168, 84-94.	0.8	56
150	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
151	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	2.2	179
152	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
153	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
154	Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Movement Disorders, 2017, 32, 246-255.	2.2	46
155	Brain tau deposition linked to systemic causes of death in normal elderly. Neurobiology of Aging, 2017, 50, 163-166.	1.5	2
156	High School Football and Late-Life Risk of Neurodegenerative Syndromes, 1956-1970. Mayo Clinic Proceedings, 2017, 92, 66-71.	1.4	81
157	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. Neurology, 2017, 89, 2271-2279.	1.5	30
158	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. Movement Disorders, 2017, 32, 1772-1779.	2.2	46
159	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
160	Clinicopathologic discrepancies in a populationâ€based incidence study of parkinsonism in olmsted county: 1991â€2010. Movement Disorders, 2017, 32, 1439-1446.	2.2	19
161	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	4.9	159
162	IgLON5 antibody. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e385.	3.1	172

#	Article	IF	Citations
163	Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. Mayo Clinic Proceedings, 2017, 92, 1291-1303.	1.4	50
164	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
165	[¹⁸F]AVâ€1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	2.2	136
166	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	2.1	11
167	¹⁸F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. Journal of Nuclear Medicine, 2017, 58, 632-638.	2.8	91
168	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex, 2017, 90, 138-148.	1.1	22
169	[P4â€“531]: TDPâ€43 DRIVES FASTER RATES OF HIPPOCAMPAL ATROPHY IN ALZHEIMER's DISEASE STARTING AT LEAST 10 YEARS PRIOR TO DEATH. Alzheimer's and Dementia, 2017, 13, P1553.	0.4	0
170	Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia. JAMA Neurology, 2016, 73, 123.	4.5	21
171	TDPâ€43 in the olfactory bulb in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2016, 42, 390-393.	1.8	9
172	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSPâ€C. Movement Disorders, 2016, 31, 653-662.	2.2	60
173	P1â€270: AVâ€1451 TAUâ€PET in Clinical Variants of Progressive Supranuclear Palsy. Alzheimer's and Dementia, 2016, 12, P518.	0.4	0
174	ICâ€Pâ€188: AVâ€1451 TAUâ€PET In Clinical Variants of Progressive Supranuclear Palsy. Alzheimer's and Dementia, 2016, 12, P136.	0.4	0
175	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not aÂHomogeneous Clinical Entity. Journal of Alzheimer's Disease, 2016, 55, 1019-1029.	1.2	24
176	Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 28, 107-111.	1.1	19
177	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
178	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
179	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
180	The clinical spectrum and natural history of pure akinesia with gait freezing. Journal of Neurology, 2016, 263, 2419-2423.	1.8	21

#	Article	IF	Citations
181	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 2016, 132, 931-933.	3.9	116
182	Alien Hand Syndrome. Current Neurology and Neuroscience Reports, 2016, 16, 73.	2.0	59
183	Coprophagia in neurologic disorders. Journal of Neurology, 2016, 263, 1008-1014.	1.8	18
184	Regional Î²â€amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia. European Journal of Neurology, 2016, 23, 313-319.	1.7	17
185	Updated TDP-43 in Alzheimerâ€™s disease staging scheme. Acta Neuropathologica, 2016, 131, 571-585.	3.9	244
186	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. NeuroImage: Clinical, 2016, 11, 90-98.	1.4	10
187	Progressive supranuclear palsy: progression and survival. Journal of Neurology, 2016, 263, 380-389.	1.8	55
188	Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. Neurocase, 2016, 22, 55-59.	0.2	11
189	Neuropsychological Profiles Differ among the Three Variants of Primary Progressive Aphasia. Journal of the International Neuropsychological Society, 2015, 21, 429-435.	1.2	78
190	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	1.2	27
191	TAR DNAâ€binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. Annals of Neurology, 2015, 78, 697-709.	2.8	96
192	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain and Language, 2015, 142, 45-53.	0.8	49
193	Frontotemporal dementia: a peek under its invisibility cloak. Lancet Neurology, The, 2015, 14, 236-237.	4.9	0
194	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117.	1.2	19
195	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. Neurobiology of Aging, 2015, 36, 1245-1252.	1.5	83
196	Key emerging issues in progressive supranuclear palsy and corticobasal degeneration. Journal of Neurology, 2015, 262, 783-788.	1.8	21
197	Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. European Journal of Neurology, 2015, 22, 745-752.	1.7	106
198	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170

#	Article	IF	Citations
199	When DLB, PD, and PSP masquerade as MSA. Neurology, 2015, 85, 404-412.	1.5	272
200	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex, 2015, 69, 220-236.	1.1	133
201	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. Journal of Neurology, 2015, 262, 2064-2072.	1.8	10
202	Primary Progressive Apraxia of Speech: Clinical Features and Acoustic and Neurologic Correlates. American Journal of Speech-Language Pathology, 2015, 24, 88-100.	0.9	69
203	Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. Journal of Neurology, 2015, 262, 1483-1492.	1.8	53
204	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
205	Minds on replay: musical hallucinations and their relationship to neurological disease. Brain, 2015, 138, 3793-3802.	3.7	40
206	Unlocking the mysteries of TDP-43. Neurology, 2015, 84, 870-871.	1.5	11
207	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
208	Phonologic errors in the logopenic variant of primary progressive aphasia. Aphasiology, 2014, 28, 1223-1243.	1.4	13
209	Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech. Neurology, 2014, 82, 1729-1735.	1.5	63
210	Progranulin-associated PiB-negative logopenic primary progressive aphasia. Journal of Neurology, 2014, 261, 604-614.	1.8	69
211	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathologica, 2014, 127, 397-406.	3.9	133
212	Motor speech disorders associated with primary progressive aphasia. Aphasiology, 2014, 28, 1004-1017.	1.4	74
213	The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism and Related Disorders, 2014, 20, 180-185.	1.1	32
214	Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2014, 10, 62-66.	0.4	14
215	The neuroanatomy of pure apraxia of speech in stroke. Brain and Language, 2014, 129, 43-46.	0.8	83
216	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74

#	Article	IF	Citations
217	Staging TDP-43 pathology in Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 441-450.	3.9	278
218	APOE Îµ4 influences Î²â€amyloid deposition in primary progressive aphasia and speech apraxia. Alzheimer's and Dementia, 2014, 10, 630-636.	0.4	31
219	Amyloid burden correlates with cognitive decline in Alzheimer's disease presenting with aphasia. European Journal of Neurology, 2014, 21, 1040-1043.	1.7	9
220	The apraxia of speech rating scale: A tool for diagnosis and description of apraxia of speech. Journal of Communication Disorders, 2014, 51, 43-50.	0.8	189
221	The evolution of primary progressive apraxia of speech. Brain, 2014, 137, 2783-2795.	3.7	134
222	FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. Journal of Neurology, 2014, 261, 710-716.	1.8	60
223	TDP-43 is a key player in the clinical features associated with Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
224	TDP-43 in Alzheimerâ€™s disease is not associated with clinical FTLD or Parkinsonism. Journal of Neurology, 2014, 261, 1344-1348.	1.8	22
225	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
226	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	2.1	155
227	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism and Related Disorders, 2014, 20, 493-498.	1.1	49
228	TDP-43 AMPLIFIES MEMORY LOSS AND HIPPOCAMPAL ATROPHY IN ALZHEIMER'S DISEASE. , 2014, 10, P279-P280.		1
229	The alien limb phenomenon. Journal of Neurology, 2013, 260, 1880-1888.	1.8	75
230	Ideomotor apraxia in agrammatic and logopenic variants of primary progressive aphasia. Journal of Neurology, 2013, 260, 1594-1600.	1.8	21
231	Identification of an atypical variant of logopenic progressive aphasia. Brain and Language, 2013, 127, 139-144.	0.8	49
232	Modeling trajectories of regional volume loss in progressive supranuclear palsy. Movement Disorders, 2013, 28, 1117-1124.	2.2	36
233	Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathologica, 2013, 126, 537-544.	3.9	168
234	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurology, The, 2013, 12, 978-988.	4.9	232

#	Article	IF	Citations
235	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimerâ€™s disease presenting as logopenic progressive aphasia. Brain and Language, 2013, 127, 127-134.	0.8	53
236	Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy. European Journal of Neurology, 2013, 20, 629-637.	1.7	47
237	Criteria for the diagnosis of corticobasal degeneration. Neurology, 2013, 80, 496-503.	1.5	1,445
238	Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: An MRI and FDG-PET study. Brain and Language, 2013, 125, 245-252.	0.8	66
239	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. Brain, 2013, 136, 455-470.	3.7	37
240	Primary Progressive Aphasia and Apraxia of Speech. Seminars in Neurology, 2013, 33, 342-347.	0.5	31
241	Occupational Differences Between Alzheimerâ€™s and Aphasic Dementias. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 612-616.	0.9	7
242	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. Neurology, 2013, 81, 337-345.	1.5	142
243	Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. European Journal of Neurology, 2013, 20, 1417-1422.	1.7	54
244	Neuropsychiatry of corticobasal degeneration and progressive supranuclear palsy. International Review of Psychiatry, 2013, 25, 197-209.	1.4	28
245	TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology, 2012, 79, 717-718.	1.5	81
246	Imaging brain atrophy in progressive supranuclear palsy and corticobasal syndromes: potential for diagnosis and monitoring of disease progression. Neurodegenerative Disease Management, 2012, 2, 589-598.	1.2	0
247	Recent Advances in the Imaging of Frontotemporal Dementia. Current Neurology and Neuroscience Reports, 2012, 12, 715-723.	2.0	39
248	Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia. Neurocase, 2012, 18, 478-488.	0.2	63
249	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain, 2012, 135, 1522-1536.	3.7	325
250	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurology, The, 2012, 11, 868-877.	4.9	355
251	Primary lateral sclerosis as progressive supranuclear palsy: Diagnosis by diffusion tensor imaging. Movement Disorders, 2012, 27, 903-906.	2.2	11
252	Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid. European Journal of Neurology, 2012, 19, 1440-1446.	1.7	20

#	Article	IF	Citations
253	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
254	Disrupted thalamocortical connectivity in PSP: A resting-state fMRI, DTI, and VBM study. Parkinsonism and Related Disorders, 2011, 17, 599-605.	1.1	146
255	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	3.8	4,176
256	Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathologica, 2011, 122, 137-153.	3.9	375
257	Ifosfamide associated myoclonus-encephalopathy syndrome. Journal of Neurology, 2011, 258, 1729-1731.	1.8	26
258	Imaging Signatures of Molecular Pathology in Behavioral Variant Frontotemporal Dementia. Journal of Molecular Neuroscience, 2011, 45, 372-8.	1.1	61
259	Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau). Journal of Molecular Neuroscience, 2011, 45, 384-389.	1.1	295
260	Gray matter correlates of behavioral severity in progressive supranuclear palsy. Movement Disorders, 2011, 26, 493-498.	2.2	43
261	Predicting functional decline in behavioural variant frontotemporal dementia. Brain, 2011, 134, 432-448.	3.7	45
262	The corticobasal syndromeâ€“Alzheimerâ€™s disease conundrum. Expert Review of Neurotherapeutics, 2011, 11, 1569-1578.	1.4	65
263	Clinical Correlates of White Matter Tract Degeneration in Progressive Supranuclear Palsy. Archives of Neurology, 2011, 68, 753-60.	4.9	110
264	Neuropathology of variants of progressive supranuclear palsy. Current Opinion in Neurology, 2010, 23, 394-400.	1.8	312
265	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	3.9	222
266	Anatomical differences between CBSâ€corticobasal degeneration and CBSâ€Alzheimer's disease. Movement Disorders, 2010, 25, 1246-1252.	2.2	71
267	Caudate atrophy on MRI is a characteristic feature of FTLDâ€FUS. European Journal of Neurology, 2010, 17, 969-975.	1.7	86
268	Dementia and the TAR DNA Binding Protein 43. Clinical Pharmacology and Therapeutics, 2010, 88, 555-558.	2.3	5
269	Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?. Neurology, 2010, 75, 2212-2220.	1.5	72
270	Fluorodeoxyglucose F18 Positron Emission Tomography in Progressive Apraxia of Speech and Primary Progressive Aphasia Variants. Archives of Neurology, 2010, 67, 596-605.	4.9	93

#	Article	IF	Citations
271	REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology, 2010, 75, 494-499.	1.5	347
272	Review: Transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Neuropathology and Applied Neurobiology, 2010, 36, 97-112.	1.8	1
273	Two distinct subtypes of right temporal variant frontotemporal dementia. Neurology, 2009, 73, 1443-1450.	1.5	153
274	Rapidly Progressive Neurodegenerative Dementias. Archives of Neurology, 2009, 66, 201-7.	4.9	114
275	The clinical spectrum of stereotypies in frontotemporal lobar degeneration. Movement Disorders, 2009, 24, 1237-1240.	2.2	22
276	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders, 2009, 24, 1375-1379.	2.2	105
277	Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathologica, 2009, 118, 349-358.	3.9	114
278	Pramipexole induced compulsive behaviors abate after initiation of rotigitine. Movement Disorders, 2009, 24, 1090-1091.	2.2	2
279	Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathologica, 2008, 116, 159-167.	3.9	50
280	Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathologica, 2008, 116, 215-220.	3.9	124
281	Î²â€amyloid burden is not associated with rates of brain atrophy. Annals of Neurology, 2008, 63, 204-212.	2.8	187
282	Frontotemporal dementia and related disorders: Deciphering the enigma. Annals of Neurology, 2008, 64, 4-14.	2.8	165
283	Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiology of Aging, 2008, 29, 280-289.	1.5	221
284	Argyrophilic grains: A distinct disease or an additive pathology?. Neurobiology of Aging, 2008, 29, 566-573.	1.5	70
285	Anatomic correlates of stereotypies in frontotemporal lobar degeneration. Neurobiology of Aging, 2008, 29, 1859-1863.	1.5	40
286	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	2.1	152
287	Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy. Brain, 2008, 131, 460-472.	3.7	94
288	Clinical Aspects of TDPâ€43 Proteinopathy, Neurofilament Inclusion Body Disease and Dementias Lacking Distinctive Proteinopathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 377-382.	1.0	3

#	Article	IF	Citations
289	The anatomic correlate of prosopagnosia in semantic dementia. Neurology, 2008, 71, 1628-1633.	1.5	104
290	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics, 2008, 17, 3631-3642.	1.4	271
291	Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology, 2008, 70, 1850-1857.	1.5	220
292	Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology, 2008, 70, 25-34.	1.5	143
293	Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Current Opinion in Neurology, 2008, 21, 688-692.	1.8	173
294	Tau Negative FTLD Without Abnormal TDPâ€43 Immunoreactivity. FASEB Journal, 2008, 22, 707.13.	0.2	0
295	FRONTOTEMPORAL LOBAR DEGENERATION WITH UPPER MOTOR NEURON DISEASE/ PRIMARY LATERAL SCLEROSIS. Neurology, 2007, 69, 1800-1801.	1.5	24
296	Capgras Syndrome and Its Relationship to Neurodegenerative Disease. Archives of Neurology, 2007, 64, 1762.	4.9	89
297	Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia (bvFTD): Current Limitations and Future Directions. Alzheimer Disease and Associated Disorders, 2007, 21, S14-S18.	0.6	219
298	Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With Progranulin Gene (PGRN) Mutations. Journal of Neuropathology and Experimental Neurology, 2007, 66, 142-151.	0.9	184
299	Imaging correlates of posterior cortical atrophy. Neurobiology of Aging, 2007, 28, 1051-1061.	1.5	176
300	Hippocampal sclerosis in tau-negative frontotemporal lobar degeneration. Neurobiology of Aging, 2007, 28, 1718-1722.	1.5	47
301	Frontotemporal Lobar Degeneration. Neurologic Clinics, 2007, 25, 683-696.	0.8	35
302	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain, 2006, 129, 1385-1398.	3.7	624
303	Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology, 2006, 66, 41-48.	1.5	435
304	The relationship between histopathological features of progressive supranuclear palsy and disease duration. Parkinsonism and Related Disorders, 2006, 12, 109-112.	1.1	21
305	Visual Hallucinations in Posterior Cortical Atrophy. Archives of Neurology, 2006, 63, 1427.	4.9	70
306	Frontotemporal Lobar Degeneration Without Lobar Atrophy. Archives of Neurology, 2006, 63, 1632.	4.9	52

#	Article	IF	Citations
307	Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease. Archives of Neurology, 2006, 63, 506.	4.9	66
308	Atypical Progressive Supranuclear Palsy With Corticospinal Tract Degeneration. Journal of Neuropathology and Experimental Neurology, 2006, 65, 396-405.	0.9	129
309	Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. Annals of Neurology, 2006, 59, 200-203.	2.8	30
310	Benign Tremulous Parkinsonism. Archives of Neurology, 2006, 63, 354.	4.9	129
311	MRI correlates of alien leg-like phenomenon in corticobasal degeneration. Movement Disorders, 2005, 20, 870-873.	2.2	21
312	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Movement Disorders, 2005, 20, 982-988.	2.2	111
313	Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease. Movement Disorders, 2005, 20, 1515-1520.	2.2	18
314	Extending the clinicopathological spectrum of neurofilament inclusion disease. Acta Neuropathologica, 2005, 109, 427-432.	3.9	28
315	Mild cognitive impairment. , 2005, , 409-415.		0
316	Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase, 2005, 11, 283-296.	0.2	173
317	Neurologic manifestations in welders with pallidal MRI T1 hyperintensity. Neurology, 2005, 64, 2033-2039.	1.5	214
318	Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND. Neurology, 2005, 65, 645-647.	1.5	76
319	Hippocampal Sclerosis and Ubiquitin-Positive Inclusions in Dementia Lacking Distinctive Histopathology. Dementia and Geriatric Cognitive Disorders, 2004, 17, 342-345.	0.7	44
320	Apolipoprotein E Îµ4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration. Archives of Neurology, 2004, 61, 1579.	4.9	64
321	Heterozygous Niemann-Pick disease type C presenting with tremor. Neurology, 2004, 63, 2189-2190.	1.5	45
322	Nonvasculitic autoimmune inflammatory meningoencephalitis. Neuropathology, 2004, 24, 149-152.	0.7	39
323	Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathology and Applied Neurobiology, 2004, 30, 369-373.	1.8	145
324	The Alien Limb. Practical Neurology, 2004, 4, 44-45.	0.5	18

#	Article	IF	Citations
325	Creutzfeldt-Jakob disease presenting as progressive supranuclear palsy. European Journal of Neurology, 2004, 11, 343-346.	1.7	43
326	Neurophysiologic Studies in Morvan Syndrome. Journal of Clinical Neurophysiology, 2004, 21, 440-445.	0.9	107
327	Correlation Between Antemortem Magnetic Resonance Imaging Findings and Pathologically Confirmed Corticobasal Degeneration. Archives of Neurology, 2004, 61, 1881-4.	4.9	67
328	Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank. Movement Disorders, 2003, 18, 1018-1026.	2.2	155
329	Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology, 2003, 60, 1766-1769.	1.5	120
330	Adult onset Niemann-Pick disease type C presenting with psychosis. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 528-529.	0.9	71
331	Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction. Neurology, 2003, 61, 1134-1135.	1.5	106
332	Neurofilament inclusion body disease: a new proteinopathy?. Brain, 2003, 126, 2291-2303.	3.7	176
333	A Clinicopathological Study of Vascular Progressive Supranuclear Palsy. Archives of Neurology, 2002, 59, 1597.	4.9	64
334	Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo. Neurology, 2002, 59, 645-645.	1.5	26